Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PolyRemedy names new CFO
As CFO, Mr Coughlen will be responsible for all aspects of PolyRemedy’s finance function, including accounting, financial planning and analysis, and internal policy development. In addition, Mr Coughlen
As CFO, Mr Coughlen will be responsible for all aspects of PolyRemedy’s finance function, including accounting, financial planning and analysis, and internal policy development. In addition, Mr Coughlen
Investors in the round included Piper Jaffray, Arnerich Massena & Associates, Medtronic, RiverVest Venture Partners, and other financial and strategic investors. Salient plans to use the net proceeds
Heilongjiang Tianlong Pharmaceutical Company, a subsidiary of China Sky One Medical, will purchase the breast drug for RMB10 million from Harbin Medical University. China Sky One Medical collaborated
The data demonstrated that tgAAC94, an investigational agent designed to inhibit activity of tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation, is well tolerated and may improve
Specially engineered to complement the existing offering of Cook embolization products and coils, MiraFlex high flow embodies the latest innovation in microcatheter technology designed to enhance traceability necessary
The product delivers PTH 1-34, teriparatide (PTH), a compound that has been proven to stimulate formation of new bone and reduce the risk of fractures. The ZP-PTH patch
The license grants Galenea the exclusive worldwide rights to develop, manufacture and commercialize the novel indole-based agonists, said Galenea. The licensed compounds have demonstrated potent 5-HT2C receptor agonist
When approved, the OraQuick hepatitis C virus (HCV) test is expected to be the first rapid HCV test approved by the FDA for use in the US. The
A total of 200 patients were enrolled in this 12-week, four-arm, parallel group Phase II clinical trial designed comparing 0.25mg, 0.5mg and 1mg once daily oral doses of
Mr Dodd was previously group finance director at Morse, a consulting, IT services and technology company. Before joining Morse in 2005, Mr Dodd held management positions at a